There is also a greater likelihood of detection of infiltration by non-haemopoietic neoplasms. Unexplained pancytopenia and an ... MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS. Bone marrow aspiration and trephine biopsy should be regarded as ...

However, for time-to-event outcomes (asthma, neoplasms, sensory disorders, mortality), the end of follow-up was the event date ... Main outcome measures Rates of immune related (infectious diseases, asthma), non-immune related (neoplasms, sensory disorders ... We used Cox proportional hazards models (asthma, neoplasms, sensory disorders, mortality), negative binomial models (infectious ... neoplasms, sensory disorders)60 and two non-specific morbidity outcomes (urgent and inpatient health services use, pediatric ...

mouth neoplasms. *adjustment disorders. Strengths and limitations of this study. *. This is the first known study to explore ...

Cancer: exp [neoplasms/].. Preliminary searches in Medline and Embase identified 749 and 1916 potential citations, respectively ...

neoplasms. *oncology. Background. Epidemiology of non-small-cell lung cancer. Lung cancer is the most prevalent life- ...

Ning Ding, Xin Zhang, Xue Di Zhang, Jun Jing, Shan Shan Liu, Yun Ping Mu, Li Li Peng, Yun Jing Yan, Geng Miao Xiao, Xin Yun Bi, Hao Chen, Fang Hong Li, Bing Yao, Allan Z Zhao ...

Zhigang Ren, Haiyu Wang, Guangying Cui, Haifeng Lu, Ling Wang, Hong Luo, Xinhua Chen, Hongyan Ren, Ranran Sun, Wenli Liu, Xiaorui Liu, Chao Liu, Ang Li, Xuemei Wang, Benchen Rao, Chengyu Yuan, Hua Zhang, Jiarui Sun, Xiaolong Chen, Bingjie Li, Chuansong Hu, Zhongwen Wu, Zujiang Yu, Quancheng Kan, Lanjuan Li ...

Lasting influence of early caloric restriction on prevalence of neoplasms in the rat. J Natl Cancer Inst 1971;47:1095-113. ... in which the positive association between height and mortality from malignant neoplasms emerged only after adjustment for ...

Aric J Hui, James Y Lau, Phyllis P Y Lam, Alman O M Chui, Alice S H Fan, Thomas Y T Lam, Yee-kit Tse, Raymond S Y Tang, Siew C Ng, Justin C Y Wu, Jessica Y L Ching, Martin C S Wong, Francis K L Chan, Joseph Sung ...

Results 397 blood and 268 bile MS/MS results were identified from infant cases, including 255 matched blood-bile pairs. There was significant association between blood acylcarnitine findings and postmortem interval (PMI), body mass index and liver weight. A probable cause of death was identified in 40% of sudden death cases, including 18 (2%) with a definite or highly likely cause of death as underlying metabolic disease; this represented 12 (12%) unexpected deaths in the first week of life and six (,1%) aged 7-365 days. Fatty acid oxidation disorders identified included very long chain acyl-CoA dehydrogenase deficiency, medium chain acyl-CoA dehydrogenase deficiency and carnitine transporter defects. ...

The appropriate action to be taken in primary care when dealing with a potential lung neoplasm is clear and unambiguous: all ... 1982) The Philadelphia pulmonary neoplasm research project. Clin Chest Med 3:243-256, . ...

Women with a history of benign neoplasm of meninges, benign neoplasm of brain and other parts of the central nervous system, or ... New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer ... Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA2007;297:1207-15 ... neoplasm of uncertain or unknown behaviour of meninges (ICD-10 codes D32, D33, D42 as principal diagnosis, related diagnosis, ...

GATA binding protein 3 (GATA3) is a zinc-finger pioneer transcription factor involved in diverse processes. GATA3 regulates gene expression through binding nucleosomal DNA and facilitating chromatin remodelling. Post-translational modifications modulate its activity. During development, GATA3 plays a key role in cell differentiation. Mutations in GATA3 are linked to breast and bladder cancer. GATA3 expression is a feature of the luminal subtype of bladder cancer and has implications for immune status and therapeutic response. It also has clinical relevance in squamous cell carcinomas and soft tissue sarcomas. This paper reviews the structure and function of GATA3, its role in cancer and its use and pitfalls as an immunohistochemical marker. ...

Results Of 741 eligible subjects, 658 were randomised to either FUSE (n=328) or SFV (n=330) colonoscopy and included in the analysis. Overall, 293/658 and 143/658 subjects had at least one adenoma (ADR 44.5%) and advanced adenoma (A-ADR 21.7%), respectively, while SSP was the most advanced lesion in 18 cases (SSPDR 2.7%). ADR and A-ADR were 43.6% and 19.5% in the FUSE arm, and 45.5% and 23.9% in the SFV arm, with no difference for both ADR (OR for FUSE: 0.96, 95% CI 0.81 to 1.14) and A-ADR (OR for FUSE: 0.82, 95% CI 0.61 to 1.09). No difference in SSPDR or multiplicity was detected between the two arms. In the per polyp analysis, the mean number of adenomas and proximal adenomas per patient was 0.81±1.25 and 0.47±0.93 in the FUSE arm, and 0.85±1.33 and 0.48±0.96 in the SFV colonoscopy arm (p=NS for both comparisons). ...

Results Microcarcinoids were most commonly identified in high-risk adenomas (size ≥10 mm (n=10), villous components (n=8) and/or high-grade dysplasia (n=4)). All polyps had mucosal prolapse and four displayed background fibrosis reminiscent of desmoplasia. The microcarcinoid component was most often multifocal (n=7) within the individual polyp and extended over an average length of 3.9 mm. The individual microcarcinoid cells were cuboidal with abundant eosinophilic cytoplasm. All cases had monotonous nuclei which lacked pleomorphism, hyperchromasia and mitotic activity. All available microcarcinoids were β-catenin and synaptophysin reactive and non-reactive for chromogranin and p53 with a negligible Ki-67 proliferation index (,2%). In addition, the microcarcinoids were variably reactive for p63 and/or CK 5/6, thereby demonstrating focal squamoid features. Two of the study cases were submitted with a concern for invasive carcinoma. Clinical information was available in 10 patients with up to ...

Examples of this include intraductal papillary neoplasm with associated invasive neoplasia, and mucinous cystic neoplasm with ... Neoplasms of the liver. Mod Pathol 2007;20(Suppl 1):S49-60. ...

Neoplasm. *Congenital lesions (e.g., encephalocele, concha bullosa). *Foreign body. More Differentials ...

... the ratio exceeded 150 DALYs per participant for all conditions except nutritional deficiencies and malignant neoplasms. ...

breast neoplasms. *clinical trials, phase III as topic. WHAT IS ALREADY KNOWN ON THIS TOPIC. *. Preclinical studies have ...

Results The accuracy of optical diagnosis was 0.63 (95% CI 0.54 to 0.71) at baseline, which improved to 0.79 (95% CI 0.72 to 0.86, p,0.001) after training. For polyps diagnosed with high confidence the accuracy was 0.73 (95% CI 0.64 to 0.82), which improved to 0.87 (95% CI 0.80 to 0.95, p,0.01). The accuracy of optical diagnosis after 6 months was 0.76 (95% CI 0.72 to 0.80), increasing to 0.84 (95% CI 0.81 to 0.88) considering high confidence diagnosis. The combined negative predictive value with high confidence of diminutive neoplastic lesions (adenomas and SSA/Ps together) was 0.91 (95% CI 0.83 to 0.96). ...

The FOXL2 (forkhead box L2) gene is located on chromosome 3 and encodes for forkhead box (FOX) family of transcription factors which play a critical role in various biological processes. Germline FOXL2 mutations have been identified in blepharophimosis/ptosis/epicanthus inversus syndrome. The somatic missense mutation in FOXL2 (FOXL2 C134W) is now known to be the defining molecular feature of adult-type granulosa cell tumour of the ovary, present in over 90% of cases of this tumour type. Immunohistochemistry for FOXL2 is used as a marker of sex cord-stromal differentiation. However, expression is not restricted to lesions harbouring FOXL2 mutations, and it is positive in a variety of sex cord-stromal proliferations other than adult-type granulosa cell tumour. ...

1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238. ... 1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752. ...

THE ELECTRO-ENCEPHALOGRAPHIC LOCALIZATION OF INTRA-CRANIAL NEOPLASMS (1 July, 1944) Free W. A. Cobb ...

Disease comorbidities included patients with a diagnosis of malignant neoplasms (ICD-9: 140-208; including multiple myeloma ( ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...

Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; ... Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008;299:1027- ... Predictors of metachronous colorectal neoplasms in sporadic adenoma patients. Int J Cancer 2003;105:82-7. ... One US study analysing a veteran population suggested that non-polypoid colorectal neoplasms accounted for nearly 10% of the ...

neoplasm of nasopharynx or infratemporal fossa. *Eustachian tube trauma. *Eustachian tube infection ...

Total cancer was defined as neoplasms, excluding in situ, benign, uncertain or non-well-defined cancers. Three CVD subtypes and ...

Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future ...